Q2056 Ciltacabtagene autoleucel - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Ciltacabtagene autoleucel

Brand Name:

CARVYKTI

Strength:

up to 100 million

HCPCS:

Q2056

SEER*Rx Category:

Immunotherapy

Major Drug Class:

CAR-T

Minor Drug Class:

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

Sept. 27, 2022

CMS Discontinuation Date:

Status:

In Use